{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:09:02Z","timestamp":1767838142638,"version":"3.49.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.pcad.2020.03.007","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T12:13:07Z","timestamp":1584706387000},"page":"194-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Evidence-based pharmacotherapy for prevention and management of cardiac allograft vasculopathy"],"prefix":"10.1016","volume":"63","author":[{"given":"Saad I.","family":"Mallah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassam","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fathi","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Naguib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"El Hajj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feras","family":"Bader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandeep R.","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2020.03.007_bb0005","author":"Wilhelm"},{"key":"10.1016\/j.pcad.2020.03.007_bb0010","series-title":"International thoracic organ transplant (TTX) registry data slides","first-page":"1155","volume":"Vol. 37(10)","author":"ISHLT: The International Society for Heart & Lung Transplantation","year":"2018"},{"issue":"1","key":"10.1016\/j.pcad.2020.03.007_bb0015","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacc.2016.04.033","article-title":"Allograft vasculopathy: the Achilles\u2019 heel of heart transplantation","volume":"68","author":"Chih","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.pcad.2020.03.007_bb0020","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0735-1097(97)00059-4","article-title":"Heterogeneity of cardiac allograft vasculopathy: clinical insights from coronary angioscopy","volume":"29","author":"Mehra","year":"1997","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.pcad.2020.03.007_bb0025","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.healun.2017.10.010","article-title":"The scourge and enigmatic journey of cardiac allograft vasculopathy","volume":"36","author":"Mehra","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.pcad.2020.03.007_bb0030","first-page":"79","article-title":"Cardiac allograft vasculopathy: an ongoing challenge in the care of heart transplant recipients","author":"Clarke","year":"2012","journal-title":"Cardiac Transplant"},{"issue":"1","key":"10.1016\/j.pcad.2020.03.007_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOT.0000000000000370","article-title":"Recent advances in allograft vasculopathy","volume":"22","author":"Merola","year":"2017","journal-title":"Curr Opin Organ Transplant"},{"issue":"7","key":"10.1016\/j.pcad.2020.03.007_bb0040","first-page":"E527","article-title":"Cardiac allograft vasculopathy: a review","volume":"92","author":"Lee","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.pcad.2020.03.007_bb0045","first-page":"319","article-title":"Cardiac allograft vasculopathy: a review","volume":"48","author":"Ramzy","year":"2005","journal-title":"Can J Surg"},{"issue":"17","key":"10.1016\/j.pcad.2020.03.007_bb0050","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1161\/01.CIR.103.17.2144","article-title":"Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study","volume":"103","author":"Valantine","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2020.03.007_bb0055","first-page":"1","article-title":"The significance of vascular alterations in acute and chronic rejection for vascularized composite allotransplantation","author":"Kollar","year":"2019","journal-title":"J Vasc Res"},{"issue":"25","key":"10.1016\/j.pcad.2020.03.007_bb0060","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJM199106203242507","article-title":"Chest pain in cardiac-transplant recipients: evidence of sensory reinnervation after cardiac transplantation","volume":"324","author":"Stark","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pcad.2020.03.007_bb0065","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13765","article-title":"Biomarker discovery in cardiac allograft vasculopathy using targeted aptamer proteomics","volume":"34","author":"Almufleh","year":"2020","journal-title":"Clin Transplant"},{"issue":"9","key":"10.1016\/j.pcad.2020.03.007_bb0070","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"issue":"suppl_3","key":"10.1016\/j.pcad.2020.03.007_bb0075","doi-asserted-by":"crossref","first-page":"iii9","DOI":"10.1093\/ndt\/gfl295","article-title":"Long-term cardiovascular risk in transplantation\u2014insights from the use of everolimus in heart transplantation","volume":"21","author":"Eisen","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.pcad.2020.03.007_bb0080","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1111\/ajt.13214","article-title":"The effect of everolimus initiation and calcineurin inhibitor elimination on cardiac allograft vasculopathy in de novo recipients: one-year results of a Scandinavian randomized trial","volume":"15","author":"Arora","year":"2015","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.pcad.2020.03.007_bb0085","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/ajt.13588","article-title":"Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: three-year results from the randomized SCHEDULE study","volume":"16","author":"Andreassen","year":"2016","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.pcad.2020.03.007_bb0090","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1164\/rccm.201005-0775OC","article-title":"Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation","volume":"183","author":"Bhorade","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"17","key":"10.1016\/j.pcad.2020.03.007_bb0095","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/01.CIR.0000136812.90177.94","article-title":"Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial","volume":"110","author":"Keogh","year":"2004","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.pcad.2020.03.007_bb0100","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.healun.2019.01.004","article-title":"Thrombotic events with proliferation signal inhibitor\u2013based immunosuppression in cardiac transplantation","volume":"38","author":"Witkowsky","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.pcad.2020.03.007_bb0105","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1161\/CIRCULATIONAHA.111.040360","article-title":"Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation","volume":"125","author":"Topilsky","year":"2012","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.pcad.2020.03.007_bb0110","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.healun.2013.05.015","article-title":"Attenuation of cardiac allograft vasculopathy by sirolimus: relationship to time interval after heart transplantation","volume":"32","author":"Matsuo","year":"2013","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"10.1016\/j.pcad.2020.03.007_bb0115","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jacc.2017.12.005","article-title":"Long-term sirolimus for primary immunosuppression in heart transplant recipients","volume":"71","author":"Asleh","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2020.03.007_bb0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijcard.2018.03.111","article-title":"Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: a meta-analysis","volume":"265","author":"Jennings","year":"2018","journal-title":"Int J Cardiol"},{"issue":"21","key":"10.1016\/j.pcad.2020.03.007_bb0125","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1016\/j.jacc.2019.03.499","article-title":"Incidence of malignancies in patients treated with sirolimus following heart transplantation","volume":"73","author":"Asleh","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.pcad.2020.03.007_bb0130","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1053-2498(02)00525-9","article-title":"TOR inhibitors and cardiac allograft vasculopathy: is inhibition of intimal thickening an adequate surrogate of benefit?","volume":"22","author":"Mehra","year":"2003","journal-title":"J Heart Lung Transplant"},{"issue":"1 Pt 2","key":"10.1016\/j.pcad.2020.03.007_bb0135","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1399-0012.1996.tb00661.x","article-title":"Mycophenolate mofetil (MMF) in heart transplantation: rejection prevention and treatment","volume":"10","author":"Renlund","year":"1996","journal-title":"Clin Transplant"},{"issue":"5","key":"10.1016\/j.pcad.2020.03.007_bb0140","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.healun.2006.01.003","article-title":"Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil","volume":"25","author":"Kaczmarek","year":"2006","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.pcad.2020.03.007_bb0145","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.healun.2014.11.025","article-title":"De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation\u20148-year results","volume":"34","author":"Guethoff","year":"2015","journal-title":"J Heart Lung Transplant"},{"issue":"5p1","key":"10.1016\/j.pcad.2020.03.007_bb0150","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1600-6143.2006.01282.x","article-title":"Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients","volume":"6","author":"Kuppahally","year":"2006","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.pcad.2020.03.007_bb0155","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1097\/01.TP.0000153302.27299.16","article-title":"Long-term benefits of mycophenolate mofetil after heart transplantation","volume":"79","author":"Keogh","year":"2005","journal-title":"Transplantation."},{"issue":"2","key":"10.1016\/j.pcad.2020.03.007_bb0160","first-page":"176","article-title":"Reduced progression of cardiac allograft vasculopathy with routine use of induction therapy with basiliximab","volume":"105","author":"Wang","year":"2015","journal-title":"Arq Bras Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2020.03.007_bb0165","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jacc.2019.04.056","article-title":"Accelerated allograft vasculopathy with rituximab after cardiac transplantation","volume":"74","author":"Starling","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2020.03.007_bb0170","series-title":"Transplantation proceedings","first-page":"253","article-title":"Use of anti-thymocyte globulin for induction therapy in cardiac transplantation: a review","volume":"Vol. 49, No. 2","author":"Ruan","year":"2017"},{"issue":"6","key":"10.1016\/j.pcad.2020.03.007_bb0175","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.healun.2008.02.016","article-title":"Delayed onset of cardiac allograft vasculopathy by induction therapy using anti-thymocyte globulin","volume":"27","author":"Zhang","year":"2008","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.pcad.2020.03.007_bb0180","doi-asserted-by":"crossref","first-page":"e002252","DOI":"10.1161\/CIRCHEARTFAILURE.115.002252","article-title":"Induction therapy with antithymocyte globulin in patients undergoing cardiac transplantation is associated with decreased coronary plaque progression as assessed by intravascular ultrasound","volume":"9","author":"Azarbal","year":"2016","journal-title":"Circ Heart Fail"},{"issue":"9","key":"10.1016\/j.pcad.2020.03.007_bb0185","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.healun.2006.03.024","article-title":"Ten-year follow-up of a prospective, randomized trial of BT563\/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation","volume":"25","author":"Bonaros","year":"2006","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"10.1016\/j.pcad.2020.03.007_bb0190","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.healun.2011.08.009","article-title":"Reduction of alloantibodies via proteasome inhibition in cardiac transplantation","volume":"30","author":"Patel","year":"2011","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.pcad.2020.03.007_bb0195","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5114\/kitp.2015.50567","article-title":"The role of statins in patients after heart transplantation","volume":"12","author":"Szygu\u0142a-Jurkiewicz","year":"2015","journal-title":"Polish J Cardio Thoracic Surg"},{"issue":"5","key":"10.1016\/j.pcad.2020.03.007_bb0200","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13248","article-title":"Optimal low-density lipoprotein concentration for cardiac allograft vasculopathy prevention","volume":"32","author":"Harris","year":"2018","journal-title":"Clin Transplant"},{"key":"10.1016\/j.pcad.2020.03.007_bb0205","series-title":"Seminars in vascular medicine","first-page":"401","article-title":"Statins and cardiac allograft vasculopathy after heart transplantation","volume":"Vol. 4, No. 04","author":"Kobashigawa","year":"2004"},{"key":"10.1016\/j.pcad.2020.03.007_bb0210","first-page":"135","article-title":"Statins in heart transplantation","author":"Kittleson","year":"2013","journal-title":"Clin. Transpl."},{"issue":"3","key":"10.1016\/j.pcad.2020.03.007_bb0215","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.trre.2016.01.001","article-title":"Statin therapy in cardiac allograft vasculopathy progression in heart transplant patients: does potency matter?","volume":"30","author":"Sieg","year":"2016","journal-title":"Transplant Rev"},{"issue":"8","key":"10.1016\/j.pcad.2020.03.007_bb0220","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.healun.2004.07.016","article-title":"Safety and efficacy of rosuvastatin therapy for the prevention of hyperlipidemia in adult cardiac transplant recipients","volume":"24","author":"Samman","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.pcad.2020.03.007_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.athoracsur.2020.02.005","article-title":"Preoperative statin therapy and heart transplantation outcomes","author":"Peled","year":"2020","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.pcad.2020.03.007_bb0230","series-title":"Transplantation proceedings","first-page":"1539","article-title":"Metaanalysis of statins and survival in de novo cardiac transplantation","volume":"Vol. 36, No. 5","author":"Mehra","year":"2004"},{"issue":"5","key":"10.1016\/j.pcad.2020.03.007_bb0235","first-page":"431","article-title":"Impact of simvastatin therapy after heart transplantation","volume":"30","author":"Wenke","year":"2005","journal-title":"Herz Kardiovaskul\u00e4re Erkrankungen"},{"issue":"6","key":"10.1016\/j.pcad.2020.03.007_bb0240","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1161\/01.CIR.96.6.2069","article-title":"Cardiac allograft vasculopathy: a review","volume":"96","author":"Weis","year":"1997","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.pcad.2020.03.007_bb0245","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.pcad.2020.03.007_bb0250","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00003088-200847070-00003","article-title":"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin","volume":"47","author":"Neuvonen","year":"2008","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.pcad.2020.03.007_bb0255","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"A clinician\u2019s guide to statin drug-drug interactions","volume":"8","author":"Kellick","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"8","key":"10.1016\/j.pcad.2020.03.007_bb0260","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.amjcard.2005.12.007","article-title":"Statin safety and drug interactions: clinical implications","volume":"97","author":"Bottorff","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2020.03.007_bb0265","author":"Acc.org"},{"issue":"2","key":"10.1016\/j.pcad.2020.03.007_bb0270","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1060028019871891","article-title":"Clinical controversy in transplantation: tacrolimus versus cyclosporine in statin drug interactions","volume":"54","author":"Migliozzi","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"10","key":"10.1016\/j.pcad.2020.03.007_bb0275","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM199509073331003","article-title":"Effect of pravastatin on outcomes after cardiac transplantation","volume":"333","author":"Kobashigawa","year":"1995","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.pcad.2020.03.007_bb0280","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S0735-1097(02)02340-9","article-title":"Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival","volume":"40","author":"Mehra","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.pcad.2020.03.007_bb0285","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.1016\/j.healun.2018.01.781","article-title":"Safety and tolerability of high intensity statin therapy in heart transplant patients receiving immunosuppression with tacrolimus","volume":"37","author":"Tjugum","year":"2018","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.pcad.2020.03.007_bb0290","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.1016\/j.healun.2019.01.701","article-title":"Intensity of statin therapy affects progression of coronary artery vasculopathy","volume":"38","author":"Power","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.pcad.2020.03.007_bb0295","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.healun.2019.01.172","article-title":"Higher intensity statin therapy reduces clinical endpoints after heart transplantation independent of lipid levels","volume":"38","author":"Golbus","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"10.1016\/j.pcad.2020.03.007_bb0300","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1161\/CIRCULATIONAHA.110.005249","article-title":"Donor simvastatin treatment abolishes rat cardiac allograft ischemia\/reperfusion injury and chronic rejection through microvascular protection","volume":"124","author":"Tuuminen","year":"2011","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.pcad.2020.03.007_bb0305","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1161\/CIRCULATIONAHA.119.039932","article-title":"Donor simvastatin treatment in heart transplantation: a randomized and blinded clinical trial","volume":"140","author":"Nyk\u00e4nen","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pcad.2020.03.007_bb0310","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.healun.2003.10.013","article-title":"Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation","volume":"24","author":"Mahle","year":"2005","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.pcad.2020.03.007_bb0315","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.healun.2015.10.040","article-title":"Statin therapy is not associated with improved outcomes after heart transplantation in children and adolescents","volume":"35","author":"Greenway","year":"2016","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"10.1016\/j.pcad.2020.03.007_bb0320","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/ehf2.12329","article-title":"Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients","volume":"5","author":"Asleh","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"6","key":"10.1016\/j.pcad.2020.03.007_bb0325","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3325\/cmj.2014.55.562","article-title":"Cardiac allograft vasculopathy: diagnosis, therapy, and prognosis","volume":"55","author":"Skori\u0107","year":"2014","journal-title":"Croat Med J"},{"issue":"9312","key":"10.1016\/j.pcad.2020.03.007_bb0330","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/S0140-6736(02)08154-0","article-title":"Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial","volume":"359","author":"Fang","year":"2002","journal-title":"Lancet"},{"issue":"10 Supplement","key":"10.1016\/j.pcad.2020.03.007_bb0335","doi-asserted-by":"crossref","first-page":"A811","DOI":"10.1016\/S0735-1097(15)60811-7","article-title":"The use of vitamin C and E after heart transplant revisited","volume":"65","author":"Sachdev","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.pcad.2020.03.007_bb0340","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.healun.2011.07.016","article-title":"Early vitamin C and E supplementation and cardiac allograft vasculopathy: 10-year follow-up from a randomized, controlled study","volume":"30","author":"Ujeyl","year":"2011","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"10.1016\/j.pcad.2020.03.007_bb0345","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1586\/14779072.2015.1086268","article-title":"Vitamin therapy after heart transplantation","volume":"13","author":"Patel","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"10","key":"10.1016\/j.pcad.2020.03.007_bb0350","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.CIR.101.10.1206","article-title":"Aspirin","volume":"101","author":"Awtry","year":"2000","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.pcad.2020.03.007_bb0355","first-page":"600","article-title":"Increased platelet aggregation after heart transplantation: influence of aspirin","volume":"10","author":"Dureau","year":"1991","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"10.1016\/j.pcad.2020.03.007_bb0360","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.healun.2017.06.015","article-title":"Early aspirin use and the development of cardiac allograft vasculopathy","volume":"36","author":"Kim","year":"2017","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"10.1016\/j.pcad.2020.03.007_bb0365","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13133","article-title":"Early aspirin initiation following heart transplantation is associated with reduced risk of allograft vasculopathy during long-term follow-up","volume":"31","author":"Peled","year":"2017","journal-title":"Clin Transplant"},{"issue":"7","key":"10.1016\/j.pcad.2020.03.007_bb0370","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1097\/TP.0000000000002704","article-title":"Cardiac allograft vasculopathy: the enduring enemy of cardiac transplantation","volume":"103","author":"Nikolova","year":"2019","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.pcad.2020.03.007_bb0375","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199301213280303","article-title":"A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients","volume":"328","author":"Schroeder","year":"1993","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pcad.2020.03.007_bb0380","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/00005344-200202000-00003","article-title":"Vasodilator response to nifedipine in human coronary arteries with endothelial dysfunction","volume":"39","author":"Weis","year":"2002","journal-title":"J Cardiovasc Pharmacol"},{"issue":"23","key":"10.1016\/j.pcad.2020.03.007_bb0385","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1016\/j.jacc.2017.03.598","article-title":"Angiotensin-converting enzyme inhibition early after heart transplantation","volume":"69","author":"Fearon","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.pcad.2020.03.007_bb0390","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.healun.2004.06.005","article-title":"The effect of combined angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound","volume":"24","author":"Erinc","year":"2005","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.pcad.2020.03.007_bb0395","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/147323000803600520","article-title":"Eprosartan in the primary prevention of cardiac allograft vascular disease: a double-blind prospectively randomized study using intravascular ultrasound","volume":"36","author":"Pethig","year":"2008","journal-title":"J Int Med Res"},{"issue":"1","key":"10.1016\/j.pcad.2020.03.007_bb0400","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12933-019-0925-y","article-title":"Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation","volume":"18","author":"Ram","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"10.1016\/j.pcad.2020.03.007_bb0405","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.healun.2009.02.009","article-title":"Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients","volume":"28","author":"Potena","year":"2009","journal-title":"J Heart Lung Transplant"},{"issue":"9","key":"10.1016\/j.pcad.2020.03.007_bb0410","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1111\/j.1600-6143.2005.01015.x","article-title":"Homocysteine-lowering therapy and early progression of transplant vasculopathy: a prospective, randomized, IVUS-based study","volume":"5","author":"Potena","year":"2005","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.pcad.2020.03.007_bb0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210373","article-title":"Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation","volume":"14","author":"K\u00fchl","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pcad.2020.03.007_bb0420","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1097\/TP.0000000000002944","article-title":"PCSK9 inhibitor use in heart transplant recipients: a case series and review of the literature","volume":"104","author":"Jennings","year":"2019","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.pcad.2020.03.007_bb0425","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.cardfail.2019.07.075","article-title":"Immunologic response to PCSK9 inhibitors in orthotopic heart transplant recipients: a case series","volume":"25","author":"Bikak","year":"2019","journal-title":"J Card Fail"},{"issue":"6","key":"10.1016\/j.pcad.2020.03.007_bb0430","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0002-9149(97)00524-9","article-title":"Lipid-lowering therapy and long-term survival in heart transplantation","volume":"80","author":"Stapleton","year":"1997","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.pcad.2020.03.007_bb0435","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jacl.2019.01.011","article-title":"Management of dyslipidemia in adult solid organ transplant recipients","volume":"13","author":"Warden","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2020.03.007_bb0440","series-title":"Transplantation proceedings","first-page":"2406","article-title":"Granulocyte colony-stimulating factor therapy is associated with a reduced incidence of acute rejection episodes or allograft vasculopathy in heart transplant recipients","volume":"Vol. 45, No. 6","author":"Vrtovec","year":"2013"},{"issue":"2","key":"10.1016\/j.pcad.2020.03.007_bb0445","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0735-1097(98)00234-4","article-title":"Efficacy of augmented immunosuppressive therapy for early vasculopathy in heart transplantation","volume":"32","author":"Lamich","year":"1998","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.pcad.2020.03.007_bb0450","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1513\/pats.200507-073JS","article-title":"Transplant-related immunosuppression: a review of immunosuppression and pulmonary infections","volume":"2","author":"Duncan","year":"2005","journal-title":"Proc Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.pcad.2020.03.007_bb0455","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/01.CIR.0000070421.38604.2B","article-title":"Use of rapamycin slows progression of cardiac transplantation vasculopathy","volume":"108","author":"Mancini","year":"2003","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.pcad.2020.03.007_bb0460","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1161\/CIRCULATIONAHA.107.692996","article-title":"Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation","volume":"116","author":"Raichlin","year":"2007","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pcad.2020.03.007_bb0465","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.1016\/j.healun.2006.11.419","article-title":"398: premature termination of a prospective, open label, randomized, multicenter study of sirolimus to replace calcineurin inhibitors (CNI) in a standard care regimen of CNI, MMF and corticosteroids early after heart transplantation","volume":"26","author":"Hunt","year":"2007","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.pcad.2020.03.007_bb0470","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ejcts\/ezu098","article-title":"Delayed therapy with clopidogrel and everolimus prevents progression of transplant arteriosclerosis and impairs humoral alloimmunity in murine aortic allografts","volume":"47","author":"Heim","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"issue":"1","key":"10.1016\/j.pcad.2020.03.007_bb0475","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1345\/aph.1H394","article-title":"Clopidogrel-precipitated rhabdomyolysis in a stable heart transplant patient","volume":"41","author":"Burton","year":"2007","journal-title":"Ann Pharmacother"},{"issue":"10","key":"10.1016\/j.pcad.2020.03.007_bb0480","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20176225","article-title":"Methotrexate associated to lipid core nanoparticles improves cardiac allograft vasculopathy and the inflammatory profile in a rabbit heart graft model","volume":"50","author":"Fiorelli","year":"2017","journal-title":"Braz J Med Biol Res"},{"issue":"12","key":"10.1016\/j.pcad.2020.03.007_bb0485","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1097\/TP.0000000000002404","article-title":"CXCR4 antagonist reduced the incidence of acute rejection and controlled cardiac allograft vasculopathy in a swine heart transplant model receiving a mycophenolate-based immunosuppressive regimen","volume":"102","author":"Hsu","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.pcad.2020.03.007_bb0490","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.trim.2018.04.002","article-title":"Effects of different serotonin receptor subtype antagonists on the development of cardiac allograft vasculopathy in murine aortic allografts","volume":"49","author":"Gocht","year":"2018","journal-title":"Transpl Immunol"},{"issue":"06","key":"10.1016\/j.pcad.2020.03.007_bb0495","first-page":"503","article-title":"Reduction of transplant vasculopathy by intraoperative nucleic acid-based therapy in a mouse aortic allograft model","volume":"66","author":"Arif","year":"2018","journal-title":"Thorac Cardiovasc Surg"},{"issue":"7","key":"10.1016\/j.pcad.2020.03.007_bb0500","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000000804","article-title":"Small molecule tyrosine kinase inhibitor nintedanib reduces development of cardiac allograft vasculopathy in murine aortic allografts","volume":"4","author":"Gocht","year":"2018","journal-title":"Transplant Direct"},{"issue":"3","key":"10.1016\/j.pcad.2020.03.007_bb0505","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/TP.0000000000002448","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, attenuates development of cardiac allograft vasculopathy in a murine heart transplant model","volume":"103","author":"Wang","year":"2019","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.pcad.2020.03.007_bb0510","doi-asserted-by":"crossref","first-page":"12393","DOI":"10.1021\/acsnano.9b05115","article-title":"Nanodelivery of mycophenolate mofetil to the organ improves transplant vasculopathy","volume":"13","author":"Uehara","year":"2019","journal-title":"ACS Nano"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003306202030061X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003306202030061X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:16:35Z","timestamp":1758500195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003306202030061X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":102,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S003306202030061X"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2020.03.007","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence-based pharmacotherapy for prevention and management of cardiac allograft vasculopathy","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2020.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}